EMA Approves Two Hybrid Medicines

The European Medicines Agency has recommended granting marketing authorization for two medications – Agilus for the treatment of malignant hyperthermia, and Neoatricon for the treatment of hypotension in neonates, infants, and children.

Agilus contains dantrolene sodium and works by preventing the release of calcium from the sarcoplasmic reticulum. Neoatricon contains dopamine hydrochloride and works by increasing systemic vascular resistance and blood pressure. Both medications have been deemed to be of satisfactory quality and bioequivalence compared to their reference products.

Agilus is indicated for use in adults and children of all ages, while Neoatricon should be prescribed by pediatric specialists. Both medications may cause side effects such as muscle weakness and headache, respectively.

Source link

error: Content is protected !!